Kedaruratan Ginjal Hipertensi.ppt

HYPERTENSIONEmergencies & Urgencies

HYPERTENSIONEmergencies & Urgencies

Dr. Harun Hudari SpPD

DIVISION OF TROPICAL INFECTIOUS DISEASESDEPARTMENT OF INTERNAL MEDICINE

SCHOOL OF MEDICINE, SRIWIJAYA UNIVERSITYMOH. HOESIN HOSPITAL

PALEMBANG

Content

• Introduction• Definitions• Prevalence/morbidity/mortality• Etiology & pathophysiology• Diagnosis• Causes• Differential diagnoses• Workup• Management• Treatment• Pharmacology IV Anti-hypertensives• References

Introduction

• Hypertension(HPT) very common Western soc.• 50 mil. US – affected (world - approx. 1 billion people)• Despite awareness + treatment still 30% adults unaware• 40% known with HTN - not on treatment• 60% on treatment BP not controlled to <140/90 mm Hg

• New data – shown incr. lifetime risk of HPT - incr. risk of CVS complications with “normal” BP levels

Classification OF HYPERTENSION

• Joint National Committee (JNC – 7) introduced a new classification system for HTN – 2004

• Normal – SBP<120 and DBP<80• Prehypertension – SBP 120-139 or DBP 80-89• Stage I hypertension – SBP 140-159 or DBP 90-

99• Stage II hypertension – SBP >160 or DBP >100• Stage II HPT further divided into:

– Hypertensive urgency– Hypertensive emergency

Other Terminology

• Severely elevated BP (JNC VII)• Defined as BP > 180/120

• “accelerated HPT”– term used to describe individuals with chronic

hypertension with associated group 3 Keith-Wagener-Baker retinopathy

• “malignant HPT”– describe those individuals with group 4 KWB

retinopathy changes + papilledema

Definitions

• HPT emergency(crisis): Is characterized by a severe elevation in BP, complicated by evidence of impending or progressive target/end organ dysfunction

VS

• HPT urgency: is a severe elevation in BP without progressive target organ dysfunction

NB – these definitions do not specify absolute BP levels

Definitions

• Emergencies– Symptomatic– Acute End-Organ Damage– Diastolic B.P. usually >130 mmHg

• Urgencies– Asymptomatic– NO Acute End-Organ Damage– Diastolic B.P. usually >110 mmHg; Systolic

B.P. usually >180 mmHg

Conditions constituting evidence of EOD

• Hypertensive encephalopathy• Intracerebral heamorrhage• Stroke• Head trauma• Ischemic heart disease (most common)

– AMI– Acute LVF with P/oedema– Unstable angina

• Aortic dissection• Eclampsia• Life threatening arterial bleed

Prevalence/ morbidity/ mortality

Prevalence:- With progress in anti-hypertensive Rx – decrease in the lifetime

incidence of HPT emergencies from 7% to 1%- Hypertensive crisis more common among elderly and black patients- Studies – HPT related problems amount for 25% of all pt visits to

medical section of ED. 33% of these - HTN emergencies.

Morbidity/mortality - Dependent on the extent of EOD on presentation and the degree to

which BP is controlled subsequently.- 1year survival rate has increased from 20% to more than 90% with

appropriate treatment.- 10-year survival rate approaches 70% with approp treatment- 1-year and 5-year mortality rate - following untreated HPT

emergency are 70 to 90% and 100% respectively

Etiology• Most common - rapid unexplained rise in BP in pt with chronic essential HPT- most have history of poor treatment/compliance or an abrupt discont

of their meds

• Other causes- Renal parenchymal disease (80% of sec.causes)- Systemic disorders with renal involvement (SLE)- Renovascular disease (Atheroscleroses/fibromuscular dysplasia)- Endocrine ( phaeochromocytoma/cushing syndrome)- Drugs (cocaine/amphetam/clonidine withdrawal/diet pills)- CNS (trauma or spinal cord disorders – Guillain-Barre- Coarctation of the aorta- Preeclampsia/Eclampsia- Postop. HPT

Pathophysiology

• Not well understood• Failure of normal autoregulation + abrupt rise in SVR• Increase in SVR due to release of humoral vasoconstrictors

from the stressed vessel wall.• Endothelium plays a central role in BP homeostasis via

substances as Nitric oxide and prostacyclin • Increased pressure starts a cycle of - endothelial damage - local activation of clotting cascade - fibrinoid necrosis of small vessels - release of more vasoconstrictors• Process leads to progressive increase in resistance and

further endothelial dysfunction

PathophysiologyPathophysiology

• Single organ inv. in approximately 83%• Two organ inv found in 14%• Multiorgan involvement found in 3% of pts

• Most common clinical presentations - cerebral infarction(24%) - pulmonary oedema (22%) - HPT encephalopathy(16%) - Cong. HF (12%)

• Less common presentations – IC hemorrhage, aortic dissection and eclampsia

Case example - HPT Case example - HPT EncephalopathyEncephalopathy

• 52yr male presents to ED• worsening headache and confusion, numbness and weakness

involving right side of body, blurry vision over past 12 hrs• PMx: HPT, bilateral artery stenosis, cocaine abuse,

hyperlipidemia.• Exam:

– BP 213/134– confused, papilledema on fundoscopy– Mild motor weakness (4/5) right arm– Lab studies rased creatinine– ECG – LVH– CT Brain – diffuse bilateral white matter changes – HPT

encephalopathy

Case example – HPT Case example – HPT EncephalopathyEncephalopathy

• Mx– admitted ICU– started on IV Nitroprusside– BP decreased to 190/100 mmHg over first 3hrs

• Outcome:– Neurology symptoms resolved within 5hrs– he was switched to his usual oral regimen on

3rd day in hospital– discharged day 5 – controlled BP

Hypertensive encephalopathy

• Clinical manifestation of cerebral edema and microhemorrhages seen with dysfunction of cerebral autoregulation

• Defined as an acute organic brain syndrome or delirium in the setting of severe hypertension

HTN Encephalopathy

• Symptoms– Severe headache– Nausea and vomiting– Visual disturbances– Confusion– focal or generalized

weakness

• Signs– Disorientation– Focal neurologic

defects– Focal or generalized

seizures– nystagmus

HPT Encephalopathy

• Not adequately treated – cerebral heamorrhage, coma and death.

• BUT with proper treatment – completely reversible

• Clinical diagnoses (exclusion)

Hypertensive Retinopathy

• Fundoscopy used to be considered a definitive tool in diagnosing HTN encephalopathy

• NOW – still usefull in recognizing acute EOD as in HTN encephalopathy, but the absence of retinal exudates, hemorrhages, or papilledema does not exclude the diagnoses.

• Fundoscopy findings

HPT Retinopathy - Fundoscopy

• Keith-Wagener classification– Stage I arteriolar sclerosis with thickening, irregularity

and tortuosity– Stage II AV dipping or compression– Stage III Flame shaped haemorrhages and cotton

wool spots– Stage IV Papilledema

• “presence of stage III and IV lesions – implies failure of the CNS vascular autoregulation and makes the Dx of Malignant HPT definitive”

HPT Retinopathy

AV crossing changes

HPT retinopathy

HPT retinopathy

PanOptic ophtalmoscope

Diagnosis• History

1) focus on presence of Sx of end-organ dysfunction(eod) 2) any identifiable etiology

• Hypertension Hx– last known normal BP– prior diagnoses + Rx– dietary and social factors

• Medication– Steroid use– Estrogens– Sympathomimetics– MAO inhibitors

• Social history– smoking, alcohol– illicit drugs (cocaine, stimulants)

• Family history– early HPT in family members– cardiovascular and cerebrovascular disease– Diabetes– Pheochromocytoma

• Pregnant?

Diagnoses• History (cont)• Symptom spesific Hx – suggesting EOD• CVS Hx

– previous MI/angina/arrhythmias – chest pain/SOB/Sx of CF/claudication/flank or back pain

• Neurologic Hx– prior strokes, neuro dysfunction– visual changes, blurriness, loss of visual fields, severe headaches,

nausea and vomiting, change in mental status• Renal Hx

– Underlying renal disease (RF)– Acute onset changes in renal frequency (anuria/oliguria)

• Endocrine Hx– diabetes, thyroid dysfunction, Cushing’s syndrome

Begin Treatment!Begin Treatment!This is a Hypertensive This is a Hypertensive EmergencyEmergency

Begin to look for other causes of symptomsBegin to look for other causes of symptoms

DiagnosesExamination1) Confirm elevated BP

» Proper position, appropriate cuff size» Supine and standing and both arms

2) Asses – EOD present• Fundoscopy

• Chronic HPT will have findings• Acute changes

new retinal bleedsSuperficial/flame shapedDeep/punctuate

exudates hard/cotton wool spots papilledema

• NeckEnlarged thryoid, carotid bruit, jugular venous distention

• CVSEnlarged heart, S3, asymmetric pulses, arrhythmias

• PulmonarySigns of LV dysfunction ( crackles, rhonchi)

• RenalRenal bruit, abdominal masses

• NeurologicLevel of consciousness, evidence of stroke, any focal signs

WorkupWorkup• Lab studies- Electrolytes, urea and creatinine- FBC and smear- Urinalysis – dipstix + microscopy- Optional - tox screen - BHCG - Endocrine testing

• Imaging studies- CXR (chest pain or SOB)- Head CT/MRI brain (abn neurology)- Chest CT/TEE/Aortic angio (Aortic dissection)

• Other Tests- ECG

ManagementManagement• ED considerations

- Many HPT pts – only small number will require emergent treatment

- Primary goal of EP?

The pts – syptoms of EOD and require immediate iv parenteral therapy.

VS

The pt with acutely elev BP(SBP>200 or DBP>120) without EOD symptoms, who require initiation of medical therapy and close follow up as outpatient /inpatient

ManagementManagement

• The EP must be capable of:

- Appropriately evaluating pts with an elevated BP- Correctly classify the HPT- Determine the aggressiveness and timing of

therapeutic interventions- Making disposition decisions

Remember - “treat the patient and not the number”

TreatmentTreatment

• Prehospital care

- Address the manifestations of a HPT emergency eg.chest pain or HF

- Reduction of BP not indicated in prehospital setting

- Rapid lowering of BP can critically decrease end-organ perfusion

TreatmentTreatment• ED Care - general principles

1. Consider context of elevated BP (pain, anxiety)2. Screen for EOD (Hx/workup) - Pts without evidence of EOD – d/c + f/up

Misconception - never d/c patient from ED with elevated BP ? - oral nifedipine – NOT indicated and may be dangerous!

- Pts with EOD – require ICU admission and rapid but gradual lowering of BP - using IV meds.

3. BP should not be lowered to normal levels- Rapid reduction in BP – below the autoregulatory range results in reduction in organ

blood flow – risk of ischemia and infarction- General rule – the MAP should be lowered by no more than 20% - 1st hour

remains stable - BP lowered to 160/110 in next 2-6hrs NB Exceptions

- BP goals best achieved by a continuous infusion of a short-acting, titratable, parenteral anti-HPT agent, along with constant intensive patient monitoring

TreatmentTreatment

• Medication options

1. Oral antihypertensives• Chronic hypertensive• Hypertensive urgency

2. IV antihypertensives• Hypertensive emergency

Principles of Therapy

• Lower B.P. over hours– Initial goal B.P.Initial goal B.P. 160’s/90’s

• Too rapid lowering may cause dire consequences (CVA, MI)

• May take several days to get to reasonable levels

• Avoid medications that cannot be controlled (sublingual nifedipine)

Pharmacology – IV anti-HPTPharmacology – IV anti-HPT

1. Vasodilators• Sodium nitroprusside• Nitroglycerin• Nicardipine• Fenoldapam• Hydralazine• Enalapril

2. Adrenergic inhibitors• Labetalol• Esmolol• Phentolamine

“IDEAL IV ANTI-HYPERTENSIVE”

• Lower the BP without compromising blood flow to critical organs

• Vasodilators generally considered 1st , because they preserve organ blood flow in the face of reduced perfusion and also tend to increase CO.

Profile of an ideal IV Profile of an ideal IV antihypertensiveantihypertensive

• Preserves GFR and renal blood flow• Few or no drug reactions• Little or no potential for exacerbation of co-morbid conditions• Rapid onset and offset of action• Minimal hypotension “overshoot”• Minimal need for continuous BP monitoring and frequent

dose titration• No acute tolerance• Ease of use and convenience• Safe and no toxic metabolites• Multiple formulations for short and long term use• Minimal symphathetic activation

Hypertensive Emergencies: Treatment

• For most patients the greatest risk of treating a hypertensive emergency is the risk of accompanying hypotension.

• Treat with short acting, easily titratable, I.V. drug.

Parenteral Drugs for Treatment of Hypertensive Emergencies

Drug Dosage Onset Duration Adverse

Effects

Indic.(I)

Contrain.(C)

VasodilatorsNitroprus-side

0.3-10 mcg/kg/minIV infusion

1-2 min. 1-2 min. N/V,mus. twitch.,cyanide, thiocyan. tox. intracran.pressure

I: CHF, aortic dissect.,

catechol.

C: hepatic, renal insuff.

Nitrogly-cerin (IV)

5-100mcg/kg/min

2-5 min. 3-5 min. HA, dizziness,vomit., methemglo.tolerance

I: coronary dis., CHFC: CVA intracran. pressure


Diazoxide (Hyperstat

IV)

1-3 mg/kg (up to 150 mg) IV bolus, q5-15 min; repeat q4-24 hr as needed

2-4 min 3-12 hr Nausea, hypotension, flushing, tachycardia, hypergly-

cemia, aggravation of angina, fluid retention

C: Syndromes of coronary insufficiency, (unless used with beta-blocking agent), cerebrovascular accident, hypersensi-

tivity to sulfonamides


Fenoldopam mesylate (Corlopam)

0.1-1.7 micrograms/kg/min IV infusion

5-15 min

1-4 hr Headache, dizziness, flushing, increased intraocular pressure,hypokalemia, dose-related tachycardia

I: Severe hyperten-sion with renal insuffi-ciencyC: Glaucoma

Hydralazine HCl (Apresoline)

10-20 mg IV or IM bolus, repeat q4-6 hr as needed (maximum dose, 40 mg)

10-20 min

3-8 hr Tachycardia, flushing, headache, vomiting, aggravation of angina

I: CHFC: Coronary insufficiency, aortic dissection, cerebrovas-cular accident (may increase intracranial pressure)


Enalaprilat(Vasotec I.V.)

1.25-5 mg q6 hr IV

15 min

6 hr Precipitous drop in blood pressure in high-renin states, variable response

I: CHFC: Use with caution in patients with severe renal insufficiency (not receiving dialysis)

Nicardipine HCl (Cardene)

5-15 mg/hr IV infusion

5-20 min

1-2 hr

Tachycardia, headache, flushing, local phlebitis

C: Greater than first-degree heart block, CHF


Adrenergic InhibitorsPhentol-amine (Regitine)-blocker

5-20 mg IV, repeat as necessary

1-2 min

10-30 min

Tachycardia, nausea, flushing, abdominal pain, aggravation of angina

I: Catecholamine excessC: Syndromes of coronary insufficiency

Esmolol HCl (Brevibloc)

200-500 micrograms/kg/min over 1-4 min, then 50-300 micrograms/kg/min IV infusion

1-2 min

10-20 min

Hypotension, nausea, bradycardia or heart block, dizziness

I: Syndromes of coronary insufficiencyC: Greater than first-degree heart block, CHF


Labetalol HCl (Normo-dyne, Trandate)- blocker

20-80 mg IV bolus, repeat as needed (maximum dose, 300 mg); or 2 mg/min IV infusion

2-10 min 2-4 hr Hypoten-sion, nausea, itching, scalp tingling, dizziness

I: Synd-romes of coronary insuffi-ciency, catechol-amine excessC: > first-degree heart block, CHF, bronchial asthma

Sodium NitroprussideSodium Nitroprusside(Hypoten L)

• MoA:

– Direct smooth muscle dilator (art + ven)– Nitric oxide compound– Potent preload and afterload reducer– Causes cerebral vasodilation

• Ultra short acting• Immediate onset - DoA : 10min• Dose: 0.1-0.5mcg/kg/min IV infusion titrate to desired effect rates>10mcg/kg/min – cyanide toxicity

• Adverse affects/Precautions:

– Cyanide and thiocyanate toxicity (pts with liver/renal dysfunction) Max dose, max 10min– Can cause precipitous drop in BP (hypotensive effects unpredictable) Ideally Art.line with continuous BP monitoring– Causes significant reflex tachycardia ( incr Oxygen demand) (angina/aortic dissection/cerebral oedema)– Nausea and vomiting– Increased ICP

• Drug of choice:

– Perioperative HPT– Cocaine toxicity– Aortic dissection(combination)– Neurologic syndromes

NitroglycerinNitroglycerin(Nitrocine / Isoket / Tridal)

• MoA:– Potent vasodilator (nitric oxide compound)– Primary affects the venous system, decrease preload (CO + BP)– Decreases coronary vasospasm

• Dose: cont infusion start 5mcg/min, incr by 5mcg/min every 3-5min to 20mcg/min If NO Response increase by 10mcg/min every 3-5min,up 200mcg/min• Onset : 2-5min/DoA : 5-10min

• Adverse effects/precautions:– Constant monitoring is essential– Tolerance from uninterrupted use (12hr withdrawal)– Headache, tachycardia, flushing

• Contra ind: – Concurrent use with PDE-5 inhibitors - causes significant hypotension– Head trauma/cerebral haemorrhage– Severe anaemia

• Drug of choice:– Acute HF– ACS

NicardipineNicardipine(Nimodipine – Nimotop)

• Ca channel blocker – selective arterial vasodilator• Onset: 1-5min• DoA: 15-30min• Dose: start 5mg/hr IV infusion, titrate every 15min to max 15mg/hr.• Advantages:

– Cause cerebral and coronary vasodilatation• Precautions: can worsen/cause HF and liver failure can exacerbate renal insuff.• Ideal for CNS emergencies• Not available SA

FenoldapamFenoldapam(Carlopam)(Carlopam)

• New (not available SA)• MoA:

– Peripheral dopamine agonist (high vs low doses)– causes selective neuro vasodilatation– mesenteric vasodilatation– increases renal blood flow and sodium excretion

• Onset – <5min, but more gentle, lasts for 30min (titratable, predictable and stable)• Standard BP monitoring is sufficient, no toxic metabolites• Dosing:

• Start at 0.1-0.3mcg/kg/min IV infusion• May be increased in increments of 0.05-0.1mcg/kg/min every 15min, until target BP reached• Max infusion rate – 1.6mcg/kg/min

• Precautions:– Pts with glaucoma or intraocular hypertension– Dose related tachycardia can occur – angina– Close BP monitoring – Close K monitoring– Caution with raised ICP

• Drug of choice– Renal insuffiency – Strokes ( combination with nicardipine)

HydralazineHydralazine(Apresoline)

• MoA:– Decreases systemic resistance by direct vasodilation of arterioles

• Dose:– 5-20mg IV bolus or 10-40mg IM repeat every 4-6hrs

• “old school”– used too much– boluses takes 20min to work– not titratable

• Adverse effects/Precautions– tachycardia, flushing, headache– sodium and water retention– increased ICP– adjust dose in severe renal dysfunction– response may be delayed and unpredictable

• Still drug of choice in pregnancy(Eclampsia), but B-blocker/Labetalol and Fenoldapam are also safe options

• Only available PO, Dihydralazine discontinued

EnalaprilatEnalaprilat• The active component of Enalapril (hydrolyzed in liver and kidney)

• MoA:– ACE inhibitor

• Dose:– 0.625-2.5mg every 6hr IV– Not titratable

• Onset – within 30 min + long half life

• Adverse effects/Precautions– Contra-indicated – volume depletion, renal vascular disease– Prolonged ½ life

• Expensive, not available SA

LabetalolLabetalol(Trandate)

• MoA:– selective alpha blocker – will reduce vascular smooth m. resistance – non-selective Beta blocker – decrease cardiac inotropy and miocard O2 consumption, will prevent reflex

tachycardia

• Dose:– Bolus: effect in 5-10min,max effect at 20min. (DoA: 2-6hrs) 1st dose 20mg then every 10-20min 2nd dose 40mg, 3rd dose 80mg.– Cont. infusion: 0.5 – 2mg/min – titrate to response,max 300mg total dose– Difficult to titrate due to very wide dose range

• Advantages:– smooth onset– Transition to oral Rx easy (dose equivalent)– Improve cerebral bloodflow – stroke pt– No need for ICU/Arterial line

• Adverse effects/precautions– Relative CI – Heart failure, heart block, Asthma (bronchoconstriction)– Vomiting, scalp tingling– Impaired hepatic function– Elderly patients

• Contraindicated in HPT secondary to Cocaine use/Phaeochromocytoma (B-blocker effect outway the alpha effect, thus unapposed alpha constriction)

• Drug of choice:– Aortic dissection– Hypertensive emergencies

EsmololEsmolol(Brevibloc)

• MoA:– highly selective beta blocker

• Dose: (titratable)– bolus: 250-500mcg/kg IV over 1-3min– infusion: 50-100mcg/kg/min– may repeat bolus after 5min or increase infusion rate to 300mcg/kg/min

• Onset 1-2min / short acting• Adverse effect/Precautions

– Hypotension common– nausea– Asthma– 1st degree AV block– heart failure

• Contraindications– Sinus bradycardia– Heart block– Cardiogenic shock– Bronchial asthma– Uncompensated CF– pregnancy

• Drug of choice:– Aortic dissection ( with nitrate)

• Not availalble anymore

PhentolaminePhentolamine((Regitine)

• MoA:– alpha adrenergic receptor blocker

• Dose:– load 5-20mg IV every 5min or– infusion 0.2-0.5mg/min

• Onset 1-2min• Adverse effect/precautions

– tachycardia– flushing/headache– MI– cerebrovascular spasm

• Contra-indications– renal impairment– Concurrent use with PDE-5 inhibitors– coronary or cerebral arteriosclerosis

• Drug of choice– Cocaine associated HPT crisis– Pheochromocytoma HPT crisis

• Not available in SA anymore

Neurological emergenciesNeurological emergencies

• Hypertensive encephalopathy– reduce MAP by 25% or diastole to 100mmHg

over 8 hrs– If neurology worsens, suspend Rx– Drug of choice:

• Sodium nitroprusside• Labetalol


• Acute Ischemic stroke– often loss of cerebral autoregulation

– ischemic region more prone to hypoperfusion

– thus BP reduction not recommended

– unless SBP>220 or DBP>120

– UNLESS planning fibrinolysis – SBP<185

and DBP< 110

– Drug of choice:• Labetalol• Nicardipine• Sodium Nitroprusside


• Acutes ICH/SAH– Treatment based on clinical/radiographic

evidence of raised ICP– Raised ICP – MAP<130 (1st 24hrs)– No raised ICP – MAP<110– Drug of choice:

• Sodium Nitroprusside• Labetalol• Nicardipine

Cardiovascular emergenciesCardiovascular emergencies

• ACS– treat if SBP>160 and/or DBP>100– Reduce MAP by 20 -30% of baseline– nitrates should be given till symptoms

subside or until DBP<100– Drug of choice:

• Nitroglycerine• Labetalol• Nicardipine

CVS emergenciesCVS emergencies

• Acute HF (pulmonary edema)– treat with vasodilator (additional to diuretics)– Sodium Nitroprusside in conjunction with

morphine, oxygen and loop diuretic– Enalaprilat also an option

CVS emergenciesCVS emergencies

• Aortic dissection– anti-hypertensive Rx is aimed at reducing the

shear stress on aortic wall (BP and Pulse)– immediate lowering of BP – lifesaving– maintain SBP<110, unless signs of end

organ hypoperfusion– preferred Rx is combination of Morphine,

B-blocker and vasodilator– Nitroprusside + Labetalol

Other disordersOther disorders

• Cocaine toxicity/pheochromocytoma– Hpt and tachycardia rarely require spesific Rx– Alpha adrenergic blockers – preferred– B – blockers can be added, but only after

alpha blockade.– Drug of choice

• Phentolamine• Labetalol• Diazepam


• Pre-eclampsia/Eclampsia– Goal SBP<160 and DBP<110 in pre-and-

intrapartum periods.– Platelets < 100 000, BP should be

maintained < 150/100– IV Magnesium to prevent seizures– Drug of choice:

• Methyldopa• Hydralazine


• Perioperative hypertension– target BP to within 20% of baseline, except if

potential for life threatening arterial bleeding– typically related to catecholamine surge post-

op.– Drug of choice:

• B-blocker• Labetalol

LocalLocal

• Tygerberg– F1(medical outpatients)

• Nitroglycerine

– Cardiology ICU• Nitroglycerine

– Renal unit • Labetalol

– Obstetrics• Labetalol• Hydralazine

LocalLocal

• Grootte Schuur (C15)– Nitroglycerine (Tridal)

• Victoria– Nitroglycerine (Tridal/Nitrocine)– Labetalol– Can get Sodium nitroprusside

SummarySummary

• HPT crisis - serious condition - associated with EOD, if left untreated

• High mortality - untreated• Main causes – non-compliance and poorly

controlled chronic hypertension.• Urgency vs emergency• Treatment should be tailored to the individual’s

condition • HPT urgency – initial goal max 25% drop in MAP

in first 3 hours• Precipitous drop just as bad – good continuous

monitoring essential

References1. Joint National Committee on prevention, detection, evaluation and treatment of high

blood pressure.Seventh Report. Hypertension 42:2003; 1206-12522. Kitiyakara C, Guzman NJ. Malignant hypertension and hypertensive emergencies.J

Am Soc Nephrol 1998;9:1353. Vaidya CK, Ouellette JR. Hypertensive Urgency and Emergency. Hospital Physician

March 2007; 43-504. Vidt D. Hypertensive Crises: emergencies and urgencies. The Cleveland clinic

disease management project. 12 Jan 2006. Available at www.clevelandclinicmeded.com/diseasemanagement/nephrology/crises/crises.htm

5. McCowan C. Hypertensive Emergencies. Available at www.emedicine.medscape.com/emergencymedicine/cardiovascular. Updated Jan 26, 2009

6. Hollander JE. Cocaine intoxication and hypertension. Ann Emerg Med. Mar 2008;51:S18-20

7. Characteristics and management op patients presenting to the emergency department with hypertensive urgency. J.Clin Hypertens. 8:2006;12-18

8. Peck TE, Hill SA, Williams M.Pharmacology for anaesthesia and intensive care. 3rd Edition.Chapters 15 & 16,p246-269.

9. AggarwalMD, Khan IA. Hypertensive Crisis: Hypertensive emergencies and Urgencies.Cardiology Clinics 24:2006;135-146

10. Flanigan JS.Vitberg D.Hypertensive Emergency and Severe Hypertension: What to Treat, Who to Treat, and How to Treat. Med Clin N Am 90:2006;439-451

http://www.clevelandclinicmeded.com/diseasemanagement/nephrology/crises/crises.htm

http://www.emedicine.medscape.com/emergencymedicine/cardiovascular.%20Updated%20Jan%2026

Documents

Kedaruratan Ginjal Hipertensi.ppt